Peptide United

Research comparison

CJC-1295 vs GHRP-6

Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.

CJC-1295

CJC-1295 with DAC · DAC:GRF

Preclinical

CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) that binds to serum albumin, dramatically extending its half-life compared to native GHRH. It produces sustained elevation of GH and IGF-1 levels over days rather than hours. Research focuses on body composition improvements, muscle growth, and fat loss through prolonged GH axis stimulation.

Research Status

Preclinical Research

Half-Life

6–8 days (due to DAC albumin binding)

Molecular Formula

C₁₅₂H₂₅₂N₄₂O₄₂S

Molecular Weight

3647.28 Da

CAS Number

863288-34-0

Research Categories

Growth Hormone Axis

Routes of Administration

Subcutaneous (SQ)
GHRP-6

Growth Hormone-Releasing Peptide 6 · His-DTrp-Ala-Trp-DPhe-Lys-NH₂

Preclinical

GHRP-6 is one of the original synthetic GHRPs, acting as a strong ghrelin receptor agonist. It produces robust GH release accompanied by significant appetite stimulation — a property that makes it both valuable for cachexia research and distinct from cleaner GHRPs like Ipamorelin. Research also shows cytoprotective and cardioprotective properties independent of GH secretion.

Research Status

Preclinical Research

Half-Life

~15–60 minutes

Molecular Formula

C₄₆H₅₆N₁₂O₆

Molecular Weight

873.02 Da

CAS Number

87616-84-0

Research Categories

Growth Hormone Axis, Healing & Recovery

Routes of Administration

Subcutaneous (SQ)Intramuscular (IM)

Full mechanism comparison

Mechanism of action, pharmacokinetics, and research findings comparison available on the Researcher plan.

Unlock full comparison →